Go to the main webpage: Drug Approvals and Databases > Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book):
"Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book)"
'via Blog this'
Return to SkillsPlus International Info Blog - Home
SkillsPlus Intl Inc - FDA, GMP, QSR, Exemptee, and Designated Representative training courses, for more than 30 years.
Showing posts with label Orange Book. Show all posts
Showing posts with label Orange Book. Show all posts
Wednesday, January 25, 2017
Wednesday, February 3, 2016
FDA Orange Book - Newest Annual Edition Has Arrived!
It's here! The latest Orange Book Annual Edition
You might also be interested in this webpage:
FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations
Return to SkillsPlus International Info Blog - Home
SkillsPlus Intl Inc. - The Best GMP Training & cGMP Training Around
Root Cause Analysis - GMP Training
Deviation Investigation Report Writing - GMP Training
Qualstar Simulation - Advanced GMP Training That's Fun!
Monday, March 2, 2015
FDA Orange Book - New!
FDA Orange Book
Recently posted on FDA.gov:The FDA's Approved Drug Products with Therapeutic Equivalence Evaluations - PDF
According to this "Orange Book" (aka "the List"):
"The products in this list have been approved under section 505 of the
Federal Food, Drug, and Cosmetic Act. This volume is current through
December 31, 2014.
The publication, Approved Drug Products with Therapeutic Equivalence
Evaluations (the List, commonly known as the Orange Book), identifies drug
products approved on the basis of safety and effectiveness by the Food and
Drug Administration (FDA) under the Federal Food, Drug, and Cosmetic Act (the
Act). Drugs on the market approved only on the basis of safety (covered by
the ongoing Drug Efficacy Study Implementation [DESI] review [e.g., Donnatal®
Tablets and Librax® Capsules] or pre-1938 drugs [e.g., Phenobarbital
Tablets]) are not included in this publication. The main criterion for the
inclusion of any product is that the product is the subject of an application
with an effective approval that has not been withdrawn for safety or efficacy
reasons. Inclusion of products on the List is independent of any current
regulatory action through administrative or judicial means against a drug
product. In addition, the List contains therapeutic equivalence evaluations
for approved multisource prescription drug products. These evaluations have
been prepared to serve as public information and advice to state health
agencies, prescribers, and pharmacists to promote public education in the
area of drug product selection and to foster containment of health care
costs. Therapeutic equivalence evaluations in this publication are not
official FDA actions affecting the legal status of products under the Act. "
Return to SkillsPlus International Info Blog - Home
SkillsPlus Intl Inc. - The Best GMP & QSR Compliance Training Around
Wednesday, September 10, 2014
FDA - Biosimilars > Purple Book: Lists of Licensed Biological Products with Reference Product Exclusivity and Biosimilarity or Interchangeability Evaluations
Read the full announcement: Biosimilars > Purple Book: Lists of Licensed Biological Products with Reference Product Exclusivity and Biosimilarity or Interchangeability Evaluations - FDA.gov:
"The Purple Book will also enable a user to see whether a biological product licensed under section 351(k) of the PHS Act has been determined by FDA to be biosimilar to or interchangeable with a reference biological product (an already-licensed FDA biological product). Biosimilar and interchangeable biological products licensed under section 351(k) of the PHS Act will be listed under the reference product to which biosimilarity or interchangeability was demonstrated.
Separate lists for those biological products regulated by the Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation and Research (CBER) will be updated periodically."
'via Blog this'
Return to SkillsPlus International Info Blog - Home
SkillsPlus Intl Inc. - The Best GMP & QSR Compliance Training Around
"The Purple Book will also enable a user to see whether a biological product licensed under section 351(k) of the PHS Act has been determined by FDA to be biosimilar to or interchangeable with a reference biological product (an already-licensed FDA biological product). Biosimilar and interchangeable biological products licensed under section 351(k) of the PHS Act will be listed under the reference product to which biosimilarity or interchangeability was demonstrated.
Separate lists for those biological products regulated by the Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation and Research (CBER) will be updated periodically."
'via Blog this'
Return to SkillsPlus International Info Blog - Home
SkillsPlus Intl Inc. - The Best GMP & QSR Compliance Training Around
Labels:
biological,
biosimilar,
CBER,
CDER,
cgmp,
class,
clips,
course,
fda,
gmp,
interchangeability,
multimedia,
Orange Book,
PHS Act,
Purple Book,
training,
video
Wednesday, February 12, 2014
FDA Orange Book 2014 - 34th Edition
This 34th edition of the FDA Orange Book (Approved Drug Products with Therapeutic Equivalence Evaluations) is current through December 31, 2013.
View the Orange Book:
FDA Orange Book (Approved Drug Products with Therapeutic Equivalence Evaluations) - PDF
Return to SkillsPlus International Info Blog - Home
---------------
SkillsPlus Intl Inc. - The Best GMP Training & cGMP Training Around
Free GMP Training Tips
Root Cause Analysis - GMP Training
Deviation Investigation Report Writing - GMP Training
Qualstar Simulation - Advanced GMP Training That's Fun!
Labels:
Book,
download,
fda,
free,
gmp training,
online,
Orange,
Orange Book,
PDF
Subscribe to:
Posts (Atom)


